Protein a immunoadsorption clinical potential

Clinical Immunotherapeutics

Volumn 6, Issue 3, 1996, Pages 211-227

  Bertram, Juergen H ^a   Jones, Frank R ^b   Balint, Joseph P ^c,d  

^a Kentuckiana Med Oncology Associates   (United States)

^b Scius Corporation   (United States)

^c IMRÉ Corporation   (United States)

^d Southern Indiana Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; PARACETAMOL; PROTEIN A;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNITY; CANCER; CLINICAL TRIAL; COMPLEMENT ACTIVATION; HEMOPHILIA; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOADSORPTION; IMMUNOMODULATION; INFLUENZA; PRIORITY JOURNAL; REVIEW; THERAPY;

EID: 0029758102     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259520     Document Type: Article

References (91)

1. Lindmark R, Thorén-Tolling K, Sjöquist J. Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J Immunol Methods 1983; 62: 1-13
2. Langone JJ. Protein A of Staphylococcus aureux and related immunoglobulin receptors produced by streptococci and pneumonococci. Adv Immunol 1982; 32: 157-252
3. Sjögren HO, Hellström I, Bansal SC, et al. Suggestive evidence that the 'blocking antibodies' of tumor bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sei 1971; 68: 1372-5
4. Hellström KE, Hellström I, Snyder Jr HW, et al. Blocking (suppressor) factors, immune complexes and extracorporeal immunoadsorption in tumor immunity. Contemp Top 1mmunobiol 1985; 15:213-38
5. Steele G, Ankerst J, Sjögren HO. Alteration of in vitro antitumor activity of tumor-bearer sera by absorption with Staphylococcus aureus Cowan I. Int J Cancer 1974; 14: 83-92
6. Terman DS. YamamotoT. Mattiolli M. el al. Extensive necrosis of spontaneous mammary adenocarcinoma after extracorporeal perfusion over Suiphviococi'its tinrent Cou an 1. J Immunol 1980; 124: 795-805
7. Terman DS. Yamamoto T, Tillquist R. et al. Tumorieidal response induced by cytosine arabinoside after plasma perfused over immobilized protein A. Science 1980: 209: 1257-9
8. X. Holohan TV. Philips TM. BowlesC. Regression of canine mammary carcinoma after immunoadsorption therapy. Cancer Res 1982:42: 3663-8
9. Jones FR. Yoshida LH. Ladiges WC. et al. Treatment of feline leukemia and reversal of FeLV by ex vivo removal of IgG: a preliminary report. Cancer 1980: 46: 675-84
10. Snyder Jr HW. Jones FR. Day NK, et al. Isolation and characterization of circulating feline leukemia virus immune complexes from plasma of persistently infected pet cats removed by ex vivo immunoadsorption. J Immunol 1982; 128: 2726 30
11. Snyder Jr HW. Singhai MC. Hardy WD. et al. Clearance of feline leukemia virus from persistently infected pet cats treated by extracorporeal immunoadsorption is correlated with an enhanced antibody response to FeLV gp 70. J Immunol 1984; 132: 1538-43 '
12. Bansal SC. Bansal BR. Thomas HL. et al. Ex vivo removal of serum IgG in a patient with colon carcinoma. Cancer 1978: 42: 1-18
13. Ray PK. Idiculla A, Mark R. et al. Extracorporeal immunoadsorption of plasma from a colon carcinoma patient by protein A-containing non-viable Staphyhcoccus aumis Cowan I: clinical, biochemical, serological and histological évalua tion of the patient's response. Cancer 1982; 49: 1800-9
14. Messerschmidt GL. Bowles C. Dean D. et al. Phase I treatment of S. (inri'iis Cowan I immunoperfusion. Cancer Treat Rep 1982:66: 2027-31
15. Terman DS. Young JB. Shearer WT, et al. Preliminary observa lions of the effects on breast adenocarcinoma of plasma per fusion over immobilized protein A. N Engl J Med 1981: 305: 1195-200
16. Bertram JH. Grunberg SM. Shulman 1. et al. Staphylococcal protein A column: correlation of mitogenicity of perfused plasma with clinical response. Cancer Res 1985; 45: 4486-94
17. Bensinger Wl, Kinet JP. Hennen G, et al. Plasma perfused over immobilized protein A for breast cancer. N Engl J Med 1982: 306: 935
18. Kinet JP. Bensinger WI. Balland N. et al. Ex vivo perfusion of plasma over protein A columns in human mammary adenocarcinoma: role of the Fc binding capacity of protein A in the side effects and the tumoricidal response. Eur J Clin Invest 1986: 16: 50 5
19. MacKintosh FR. Bennett K. Schiff S. et al. Treatment of advanced malignancy with plasma perfused over siaphylococcal protein A. West J Med 1983; 139: 36-40
20. Ray PK. Besa E, Idiculla A. et al. Efficient removal of imnuinoglobulin G from the plasma of a multiple myeloma patient: description of a new method for treatment of hvperviscosity syndrome. Cancer 1980; 45: 2633-8
21. Besa EC. Ray PK. Swami VK. et al. Specific immunoadsorption of IgG antibody in a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. Am J Med 1981: 71 : 1035-40
22. Korec S. Schein PS. Smith FP. et al. Treatment of cancerassociated hemolytic urémie syndrome with Staphylococcal protein A immunoperfusion. J Clin Oncol 1986; 4: 210-5
23. Häkansson L. Jonsson S. Soderberg M. et al. Tumor regression after extracorporeal affinity chromatography of blood plasma across agarose beads containing staphylococcal protein A. EurJ Cancer Clin Oncol 1984:20: 1377-88
24. Wallmark A. Gmbh A. Freiburghaus C, el al. Feasibility of extracorporeal on line large scale plasma adsorptions on protein A-Sepharose columns in cancer patients. Artif Oruans 1984; 8:72-81
25. Branda RF. Miller WJ. Soltis RD. et al. Immunoadsorption of human plasma with protein A Sepharose columns. Transfusion 1986; 26: 471-7
26. Nilsson I, Jonsson S. et al. A procedure for removing high-tiler antibodies by extracorporeal protein A-sepharose adsorption in hemophilia. Blood 1981: 58: 38-44
27. Bygrcn R Freiburghaus C. Lindholm T. et al. Goodpasture's syndrome treated with staphylococcal protein A immunoadsorption. Lancet 1985; II: 1295-6
28. Palmer A. Gjorstrup P. Severn A, et al. Treatment of systemiclupus erythematosus by extracorporeal immunoadsorption. Lancet 1988; II: 272
29. Palmer A. Taube D. Welsh K, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplant. Lancet 1989: I: 10-2
30. Hakim RM. Millord E. Himtneltarb J. et al. Extracorporeal removal of HLA antibodies in transplant candidates. Am J Kidney Dis 1990: 16:423-31
31. Reisaeter AV, Leivestad T. Albrechtsen D, et al. Pretransplant plasma exchange or immunoadsorption facilitates renal trans plantation in immunized patients. Transplantation 1995: 60: 242-8
32. Dantal J. Bigot E. Bogers W. et al. Effect of plasma protein adsorption on protein excretion in kidney transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994: 330:7-14
33. Berta E. Gonfalonier P. Simoncini O. et al. Removal of anti acetylcholine receptor antibodies by protein A immunoadsorption in tnyasthenia gravis. Int J Artif Organs 1994; 17: 603-8
34. Messerschmidt GL. Henry DH. Snyder Jr HW. et al. Protein A immunoadsorption in the treatment of malignant disease. J Clin Oncol 1988:6: 203-12
35. Singhai AK. Singhai MC. Nudelman E. et al. Presence of fucolipid antigens with mono and dimeric X determinant (Lex) in the circulating immune complexes of patients with adenocarcinoma. Cancer Res 1987: 47: 5566-71
36. Hakomori S-i. Nudelman E. Kannagi R. et al. The common structure in fucosyl-lactosaminolipids accumulating in human adenocarcinomas and its possible absence in normal tissue. Biochem Biophys Res Commun 1982: 109: 36-44
37. Bertram JH. Hatch LK. The treatment of high grade astrocytoma by extracorporeal immunoadsorption with staph protein A columns [abstract 50P). Proc Am Soc Clin Oncol 1994 18: 180
38. Watson PR. Guthrie Jr TH. Caruana RJ. Cisplatin associated hemolytic urémie syndrome: successful treatment with a staphylococcal protein A column. Cancer 1989: 64: 1400-3
39. Snyder. Jr HW. Mittelman A. Oral A. et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic urémie syndrome by protein A immunoadsorption of plasma. Cancer 1993: 7Ï: 1882-92
40. Bertram JH, Snyder Jr HW. Gill PS. et al. Protein A immunoadsorption in HIV-related immune thromhocytopenia: a preliminary report. Artif Organs 1988; 12: 484-90
41. Snyder Jr HW. Bertram JH. Channel M, et al. Reduction in platelet binding immunoglobulins and improvement in platelet counts in patients with HIV-associated idiopathic thrombo-cytopenia purpura (ITP) following extracorporeal immunoadsorption of plasma over staphylococcal protein A-silica. Artif Organs 1989; 13:71-7
42. Snyder Jr HW, Bertram JH, Henry DH, et al. Use of protein A immunoadsorption as a treatment for thrombocytopenia in HIV-infected homosexual men: a retrospective evaluation of 37 cases. AIDS 1991; 5: 1257-60
43. Snyder Jr HW, Cochran SK. Balint Jr JP, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992; 79: 2237-45
44. Christie DJ, Howe RB, Lennon SS, et al. Treatment of refractoriness to platelet transfusion by protein A column therapy. Transfusion 1993; 33: 234-42
45. Mittelman A. PuccioC. AhmedZ, etal. Response of refractory thrombotic thrombocytopenic purpura to extracorporeal immunoadsorption. N Engl J Med 1992; 326: 711-2
46. Drew MJ. Resolution of refractory, classical thrombotic thrombocytopenic purpura after staphylococcal protein A immunoadsorption. Transfusion 1994; 34: 536-8
47. Weinstein R, Sachiko Sato PT, et al. Successful management of paraprotein associated peripheral polyneuropathies by immunoadsorption with staphylococcal protein A. J Clin Apheresis 1993:8:72-7
48. Olivari M-T, May CB, Johnson WS, et al. Treatment of acute vascular rejection with immunoadsorption. Circulation 1994; 90 Pt 2: II-70-3
49. Nitschke M, Hochberg F. Dropcho E. Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy. N Engl J Med 1995; 332: 192
50. Cher LM, Hochberg FH, Teruya J, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A immunoadsorption. Cancer 1995; 75: 1678-83
51. Wiesenhutter CW, Irish BL, Bertram JH. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot study. J Rheumatol 1994; 21: 804-12
52. Jones FR, Balint Jr JP, Snyder Jr HW, Prosorba® Column Clinical Trial Group. Selective extracorporeal removal of immunoglobulin G and circulating immune complexes: a review. Plasma Ther Transfus Technol 1986; 7: 333-49
53. Balint Jr JP, Jones FR. Perfusion of canine serum over Staphylococcus aureus Cowan I: evidence for release of protein A and changes in specific antibody activity. Immunol Commun 1983; 12: 573-91
54. Bergdoll MS. The enterotoxins. In: Monie TC, Kadis S, Ajl SJ, editors. Microbial toxins. Vol. 3. New York: Academic Press, 1972: 265-326
55. Balint Jr JP, Ikeda Y, Langone JL, et al. Tumoricidal response following perfusion over immobilized protein A: identification of immunoglobulin oligomers in serum after perfusion and their partial characterization. Cancer Res 1984; 44: 734-43
56. Langone JJ, Das C, Bennett D, et al. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphvlococcus aureus and immobilized protein A reagents used in serotherapy of cancer. J Immunol 1984; 133: 1057-63
57. Young JB, Ayus JC, Miller LK, et al. Cardiopulmonary toxicity in breast carcinoma patients during plasma perfusion over immobilized protein A: pathophysiology of reaction and attenuating methods. Am J Med 1983; 75: 278-88
58. Snyder Jr HW, Henry DH, Messerschmidt GL. et al. Minimal toxicity during protein A immunoadsorption treatment of malignant disease: an outpatient therapy. J Clin Apheresis 1991; 6: 1-10
59. Kabish A, Kroll, Wedi B, et al. Severe adverse effects of protein A immunoadsorption. Lancet 1994; 343: 116
60. Scully RE, Mark EJ, McNeely WF, et al. A 55 year old woman with a skin rash and hemiparesis after staphylococcal protein A column therapy. N Engl J Med 1994; 331: 792-800
61. Smith RE, Gottschall JL, Piseiotta AV. Life threatening reaction to staphylococcal protein A immunomodulation. J Clin Apheresis 1992; 7: 4-5
62. Huestis DW, Rifkin RM, Durie BGM, et al. An unexpected complication following immunoadsorption with a staphylococcal protein A column. J Clin Apheresis 1992; 7: 75-7
63. Morrison FS, Huestis DW. Toxicity of the staphylococcal protein A immunoadsorption column. J Clin Apheresis 1992: 7: 171-2
64. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion 1994; 34: 891-4
65. Balint Jr JP, Jones FR, Snyder Jr HW. Prosorba® treatment column: a device that removes circulating immune complexes (C1C), IgG, and autoimmune antibodies from patient plasma. Proc Mat Res Soc 1989; 110: 761-6
66. Kaplan AP. Initiation of the intrinsic coagulation and fibrinolytic pathways of man: the role of surfaces, Hageman factor, prekallikrein, high molecular weight kininogen and factor XI. Prog Hemostas Thromb 1978; 4: 127
67. Sato H, Yamagata Y, Kidaka T. Studies on quantitative levels of complement activation induced by immobilized and soluble forms of protein A: relevance to extracorporeal immunoadsorption. Transfus Sei 1991; 12: 299-305
68. Phillips TM, Holohan TV, Korec S, et al. The pathophysiology of circulating immune complexes: their role in host-tumor interactions and removal by immunoadsorption therapy. Contemp Top Immunobiol 1985;15: 111-37
69. Sheikh IA, Kaplan AP. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum: role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem Pharmacol 1989; 38:993-1000
70. Goodman MG, Chenoweth DE, Weigle WO. Induction of interleukin-1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. JExpMed 1982; 156:912-7
71. Dinarello CA. lnterkeukin-1 and the pathogenesis of the acute phase response. N Engl J Med 1984:311: 1413-8
72. Sachs L, Lotem J, Shabo Y. The molecular regulators of macrophage and granulocyte development: role of MGI-2/IL-6. Ann NY Acad Sei 1989; 557: 417-35
73. Clark SC. Interleukin-6: multiple activities in regulation of the hematopoietic and immune systems. Ann NY Acad Sei 1989; 557: 438-43
74. Müller-Eberhard HJ. Complement. Annu Rev Biochem 1975; 44: 697-724
75. Hu VW, Esser AF, Podack ER, et al. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. J Immunol 1981; 127: 380-6
76. Freiburghaus C, Larsson LA, Nilsson IM, et al. A summary of five years clinical experience with extensive removal of immunoglobulins. Plasma Ther Transfus Technol 1986; 7: 545
77. Per Gjörstruo P, Watt RM. Therapeutic protein A immunoadsorption: a review. Transfus Sei 1990; H: 281-302
78. Belàk M, Borberg H, Jimenez C, et al. Technical and clinical experience with protein A immunoadsorption columns. Transfus Sei 1994; 15:419-22
79. Snyder Jr HW. Ernst NR. Grosmairc LS, et al. Selective removal of antigen-complexed IgG from cat plasma by adsorption onto a protein A-silica matrix. J Immunol Methods 1987: 101:209-17
80. Woods Jr VL, Oh EH. Mason D. et al. Autoantibodies against the platelet glycoprotein lib/Ilia complex in patients with chronic 1TP. Blood 1984: 63: 368-75
81. George JN, El-Harake MA, Raskob GE. Chronic idiopathic thromhocytopenic purpura. N Engl J Med 1994: 331: 1207-11
82. Balint Jr JR Snyder Jr HW. Cochran SK. et al. Long term response of immune thrombocytopenia to extracorporeal immunoadsorption. Lancet 1991; 337: 1106
83. Balint Jr JP, Quagliata F. Cochran SK. et al. Association of anti-platelet IgG antibody with response to extracorporeal protein A/silica immunoadsorption in ITP patients. Am J Hematol 1995:50: 74-5
84. Balint Jr JP. Jones FR. Detection of elevated anti-idiotypic antibody levels in immune thrombocytopenic patients expressing anti-platelet antibody. Blood 1994; 84: 664-5
85. Balint Jr JP. Coehran SK. Jones FR. Modulation of idiotypic and antudiotypic immunoglobulin G responses in an immune thrombocytopenic purpura patient as a consequence of extra corporeal protein A immunoadsorption. Artif Organs 1995; 19: 496-9
86. Balint Jr JP. Jones FR. Evidence for proteolvtic cleavage of covalently bound protein A from a silica based extracorporcal immunoadsorbent and lack of relationship to treatment effects. Transfus Sei 1995: 16: 85-94
87. Sasano M. Burton DR, Silverman GJ. Molecular selection of human antibodies with an unconventional bacterial B cell an tigen. J Immunol 1993: 151:5822-39
88. Howe RB. Christie DJ. Protein A immunoad.sorption treatment in hematology: an overview. J Clin Apheresis 1994: 9: 31-2
89. Johnson HM, Russell JK. Pont/er CH. Staphylococcal entero toxin microbial superantigens. FASEB J 1991; 5: 2706-12
90. Kinet JP. Bensinger WI. Balland N. et al. Ex vivo perfusion of plasma over protein A columns in human mammary adenocarcinoma: evidence for protein A leaking by radioimmunoassay. Eur J Clin Oncol 1986; 16: 50-5